Olinvacimab

奥伐西单抗

Report date: 2025/12/31 20:01:55

Base Information

Drug NameOlinvacimab
Drug Alias NameTanibirumab - PharmAbcineAnti-KDR mAb - PharmAbcineTanibirumabAnti-VEGFR-2-mAb-PharmAbcineAnti-KDR mAb (PharmAbcine) +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonistsAngiogenesis inhibitors
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsNeoplasm MetastasisTriple Negative Breast NeoplasmsGlioblastoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaSouth Korea
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPharmabcine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive Companies3sbio IncPharmabcine
Active IndicationsN/A
Inactive IndicationsNeoplasm MetastasisTriple Negative Breast NeoplasmsGlioblastoma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A